Next generation histopathological diagnosis for precision medicine in solid cancers
|
|
- Kerry Ferguson
- 5 years ago
- Views:
Transcription
1 Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics University of Verona, Italy
2 Outline 1. Cancer molecular heterogeneity and clonal evolution 2. Next-generation molecular technologies 3. Next-generation pathological diagnostics
3 Emerging Molecular Taxonomy Molecular Heterogeneity Prevalence of Phenotypes of cancers
4 Emerging Molecular Taxonomy Molecular Heterogeneity Prevalence of Phenotypes of cancers Cowley MJ et al. J Hepatobiliary Pancreat Sci 2013 [Epub ahead of print] Copyright (2013) by permission of Wiley
5 Same morphology, different cancers Lung adenocarcinoma Reprinted by permission from Macmillan Publishers Ltd: Pao W & Hutchinson KE. Nat Med 2012;18(3): (2012)
6 Lung adenocarcinoma mutually exclusive molecular types Cancer Genome Atlas Research Network. Nature 2014;511(7511): (2014) Creative Commons license
7 The era of targeted therapy 1 KIT mutation 78% GIST 2 EGFR mutation 20% Lung adenocarcinoma 3 BRAF mutation 60% Melanoma 4 RAS mutations 40% Colorectal cancer Scarpa A. et al., unpublished data
8 Targeted therapy issues Targeted therapy based on single gene targeting has variable success, and development of resistance is the rule
9 Each cancer has multiple mutations Whole exome sequencing of 99 cases of pancreatic cancer Each case has an average of 60 mutations KRAS (93%), TP53 (42%), SMAD4 (20%) MLL3 (8%) PCDH15 (7%) TGFBR2 (6%) SF3B1 (5%) ARID1A (5%) ATM (5%) CDKN2A (4%) Reprinted by permission from Macmillan Publishers Ltd: Biankin AV et al. Nature 2012;491(7424): (2012)
10 Core signalling pathways are affected Global genomic analysis has revealed that several core signalling pathways are affected in each single cancer Pancreatic Cancer Pancreatic cancer: 14 cell signalling pathways altered in % of cases 100% Cowley MJ et al. J Hepatobiliary Pancreat Sci 2013 [Epub ahead of print] Copyright (2013) by permission of Wiley
11 Significantly mutated pathways in pancreatic adenocarcinomas MAPK pathway: (95%) KRAS TGFβ pathway: (40%) SMAD4 TGFBR2 ACVR2A TGFBR1 DNA damage repair: (20%) BBBB BRCA2 BRCA1 XXXX YYYY ZZZZ AAAA Nonsense, Indel Missense Homozygous deletion Germline mutation Scarpa A. et al., unpublished data
12 Significantly mutated pathways in lung adenocarcinomas RTK=90% MAPK=60% DNA repair=63% PI3K-mTOR=37% Reprinted by permission from Macmillan Publishers Ltd: Ding L et al. Nature 2008;455(7216): (2008)
13 Significantly mutated pathways in lung squamous cell carcinomas PI3K-mTOR=67% RTK=53% Cancer Genome Atlas Research Network. Nature 2013;489(7417): (2013) Creative Commons license
14 Significantly mutated pathways in colorectal carcinomas Cancer Genome Atlas Network. Nature 2012;487(7407): (2012) Creative Commons license
15 Cancer molecular heterogeneity and clonal evolution is an ongoing process Primary and metastasis clonal heterogeneity Reprinted by permission from Macmillan Publishers Ltd: Marusyk A et al. Nat Rev Cancer 2012;12(5): (2012)
16 Primary and metastasis clonal heterogeneity Genetic evolution of pancreatic cancer by comparative lesion sequencing: Progressor mutation Founder mutation Reprinted by permission from Macmillan Publishers Ltd: Yachida S et al. Nature. 2010;467(7319): (2010)
17 Primary and metastasis clonal heterogeneity Genetic evolution of pancreatic cancer by comparative lesion sequencing: Geographic mapping of primary carcinoma reveals metastatic clones Sub-clones metastasising to lung and liver Sub-clones metastasising to peritoneum Reprinted by permission from Macmillan Publishers Ltd: Yachida S et al. Nature. 2010;467(7319): (2010)
18 Primary and metastasis clonal heterogeneity Genetic evolution of pancreatic cancer by comparative lesion sequencing: FOUNDER PROGRESSOR Ongoing clonal evolution within primary carcinoma Reprinted by permission from Macmillan Publishers Ltd: Yachida S et al. Nature. 2010;467(7319): (2010)
19 Implications for therapy and companion diagnostics Primary tumours and metastasis are heterogeneous Treat by targeting founder mutations Core signalling pathways are affected Target circuitry rather than a single molecule Identification and quantification of cancer heterogeneity is crucial Molecular diagnostics is the tool
20 Clonal heterogeneity and therapy Molecular Analysis Therapy Drug Yes Anti red Yes Anti gray First line Normal Red gene mutated Gray gene mutated Anti red Second line Scarpa A. et al., unpublished data
21 Outline 1. Cancer molecular heterogeneity and clonal evolution 2. Next-generation molecular technologies 3. Next-generation pathological diagnostics
22 Sanger sequencing single gene fragment for one patient Primer design PCR Product Clean up 350 bp per PCR (1 gene fragment) Sequence reaction 4 hours - 1 hour Hands On Scarpa A. et al., unpublished data
23 Next generation sequencing multiple genes amplified simultaneously Primer design Multiplex PCR Primers Removal Up to 1Mb per multiplex PCR (~500 genes) Adaptors ligation Adapter clean-up 6 hours - 1 hour Hands On Scarpa A. et al., unpublished data
24 Next generation sequencing Starting DNA Emulsion PCR amplification - one DNA molecule per bead Clonal amplification of thousands copies Starting DNA Solid phase bridge PCR - one DNA molecule per cluster Clonal amplification of thousands copies Scarpa A. et al., unpublished data
25 Next Generation Sequencing data are quantitative Variant frequency Mutation Allelic silent SNP Solid Allelic pseudopapillary silent tumour SNP Mutation 80% neoplastic cells ß catenin mutation Each cell has two alleles CTNNB1 FGFR3 APC PIK3CA SPT27 SPT30 ß catenin mutation is heterozygous (one allele) We should find 40% of alleles mutated Scarpa A. et al., unpublished data
26 Next Generation Sequencing data are quantitative and reveal clonal composition 20% 40% 40% Normal CTNNB1 CTNNB1 + PIK3CA Scarpa A. et al., unpublished data
27 Next Generation Sequencing: simultaneous analysis of multiple genes Primer design Multiplex PCR Primers Removal Up to 1Mb per multiplex PCR (~500 genes) Adaptors ligation Different Barcodes = multiple patients Scarpa A. et al., unpublished data
28 Next Generation Sequencing: simultaneous analysis of multiple patients BLOOD FFPE Primer design Multiplex PCR Primers Removal Genomic DNA A B C D Adaptors ligation B C D A Scarpa A. et al., unpublished data Different Barcodes = multiple patients
29 Next Generation Sequencing: simultaneous analysis of multiple genes 190 PCR in one tube 46 genes, 930 mutations Colorectal cancer KRAS BRAF EGFR TP53 PIK3CA CSF1R JAK2 NRAS PTPN11 ERBB2 SRC FGFR3 NPM1 CDKN2A RET HNF1A SMAD4 GNAS PDGFRA MPL ABL1 PTEN FLT3 STK11 SMARCB1 KIT MET NOTCH1 FGFR2 RB1 JAK3 VHL KDR SMO 20µl HRAS AKT1 ALK MLH1 FBXW7 ERBB4 ATM CDH1 IDH1 CTNNB1 APC FGFR1 Scarpa A. et al., unpublished data
30 Next Generation Sequencing: simultaneous analysis of multiple genes in multiple patients Variant type (frequency) Sample CRC1 CRC2 CRC3 CRC4 CRC5 CRC6 CRC7 CRC8 CRC9 Neoplastic cells 90% 80% 85% 60% 40% 85% 55% 70% 50% Subtype MSS MSS MSS MSS MSS MSS MSS MSS MSS 61Q/H 12G/D KRAS (23%) (23%) 271E/K 245G/R R209del 278P/S 175R/H TP53 (20%) (73%) (46%) (35%) (22%) 482C/R KDR (50%) SMAD4 361R/H ATM ERBB2 CTNNB1 FBXW7 FGFR3 MET CDH1 410V/A (50%) 777V/L (43%) 45S/F (43%) 452E/Q (56%) 375N/S (59%) 72D/N (13%) (24%) 604P/S (64%) 776G/V (39%) 384F/L (61%) 375N/S (45%) Scarpa A. et al., unpublished data
31 Next Generation Sequencing data are quantitative Variant type (frequency) Sample CRC1 CRC2 CRC3 CRC4 CRC5 CRC6 CRC7 CRC8 CRC9 Neoplastic cells 90% 80% 85% 60% 10% 85% 55% 70% 50% Subtype MSS MSS MSS MSS MSS MSS MSS MSS MSS 61Q/H 12G/D KRAS (23%) (23%) 271E/K 245G/R R209del 278P/S 175R/H TP53 (20%) (73%) (46%) (35%) (22%) 482C/R KDR (50%) SMAD4 361R/H ATM ERBB2 CTNNB1 FBXW7 FGFR3 MET CDH1 410V/A (50%) 777V/L (43%) 45S/F (43%) 452E/Q (56%) 375N/S (59%) 72D/N (13%) (24%) 604P/S (64%) 776G/V (39%) 384F/L (61%) 375N/S (45%) Scarpa A. et al., unpublished data
32 Next Generation Sequencing data are quantitative A B C TP53 exon 8 (wild type) TP53 exon 8 (Arg282Trp; 20%) TP53 exon 8 (Val274Phe; 73%) Mafficini A et al. PLoS One 2014;9(8):e Creative Commons License
33 Outline 1. Cancer molecular heterogeneity and clonal evolution 2. Next-generation molecular technologies 3. Next-generation pathological diagnostics
34 Luchini C et al. J Clin Oncol 2014;32(17):e63-e66. Reprinted with permission (2014) American Society of Clinical Oncology. All rights reserved
35 Liver carcinosarcoma TP53 (F109C) TP53 (F109C) TP53 (F109C) TP53 (F109C) TP53 (F109C) Luchini C et al. J Clin Oncol 2014;32(17):e63-e66. Reprinted with permission (2014) American Society of Clinical Oncology. All rights reserved
36 Liver carcinosarcoma TP53 (F109C) TP53 (F109C) TP53 (F109C) TP53 (F109C) TP53 (F109C) Luchini C et al. J Clin Oncol 2014;32(17):e63-e66. Reprinted with permission (2014) American Society of Clinical Oncology. All rights reserved
37 Liver carcinosarcoma TP53 (F109C) Carcinosarcoma is monoclonal Report of clonal heterogeneity Targets for therapy TP53 (F109C) TP53 (F109C) TP53 (F109C) TP53 (F109C) Luchini C et al. J Clin Oncol 2014;32(17):e63-e66. Reprinted with permission (2014) American Society of Clinical Oncology. All rights reserved
38 Quantification of mutated clones Materials 100 cancers Method Sensitivity (MT/WT) Sanger sequencing 20% ARMS PCR 1% Result Sanger Result ARMS Interpretation Positive Positive High abundance Negative Positive Low abundance Negative Negative Wild Type Zhou Q et al. J Clin Oncol 2011;29(24):
39 Quantification of mutated clones Progression-free survival (PFS) Overall survival (OS) High Low WT High Low WT Zhou Q et al. J Clin Oncol 2011;29(24): Reprinted with permission (2011) American Society of Clinical Oncology. All rights reserved
40 Quantification of mutated clones Materials Methods Zhou Q et al. J Clin Oncol 2011;29(24):
41 Quantification of mutated clones Normal EGFR positive EGFR negative Zhou Q et al. J Clin Oncol 2011;29(24): Sequencing ARMS-PCR Therapy 60% + + YES 2% - + NO 2% - + YES Scarpa A. et al., unpublished data
42 Each cancer has multiple mutations Whole exome sequencing of 99 cases of pancreatic cancer Each case has an average of 60 mutations KRAS (93%), TP53 (42%), SMAD4 (20%) MLL3 (8%) PCDH15 (7%) TGFBR2 (6%) SF3B1 (5%) ARID1A (5%) ATM (5%) CDKN2A (4%) Reprinted by permission from Macmillan Publishers Ltd: Biankin AV et al. Nature 2012;491(7424): (2012)
43 Molecular Heterogeneity Lung adenocarcinoma Coexistent EGFR and TP53 mutations Scarpa A. et al., unpublished data
44 Molecular Heterogeneity Lung adenocarcinoma Response to gefitinib of EGFR mutant cancers Scarpa A. et al., unpublished data
45 Molecular Heterogeneity Lung adenocarcinoma Response to gefitinib of EGFR mutant cancers * * PMA = Proportion of mutated alleles Scarpa A. et al., unpublished data
46 Core signalling pathways are affected Global genomic analysis has revealed that several core signalling pathways are affected in each single cancer Pancreatic Cancer Pancreatic cancer: 14 cell signalling pathways altered in % of cases 100% Cowley MJ et al. J Hepatobiliary Pancreat Sci 2013 [Epub ahead of print] Copyright (2013) by permission of Wiley
47 Theranostics tomorrow Analysis of genomic data from 12 tumour types Breast, colon, lung, bladder, ovary, brain.. Ciriello G et al. Nat Genet 2013;45: Hoadley KA et al. Cell 2014; 158:
48 Map of actionable alterations across 12 tumour types RTK MTOR AURKA PARPi Ciriello G et al. Nat Genet 2013;45(10): (2013) Creative Commons license
49 Map of actionable alterations across 12 tumour types 100 Samples (%) Number of pathways altered Ciriello G et al. Nat Genet 2013;45(10): (2013) Creative Commons license
50 Challenge in molecular diagnostics 60-80% of cancer patients: - Advanced stages - Poor performance status Cytology Limited quantity of cancer sample NGS & cytology Scarpa A. et al., unpublished data
51 Challenge in molecular diagnostics Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 36/38 (95%) adequate libraries EGFR KRAS TP53 PIK3CA BRAF STK11 6/36 (16%) 10/36 (28%) 7/36 (18%) 3/36 (8%) 2/36 (5%) 1/36 (3%) 24/36 (67%) at least one 9/36 (25%) multiple Scarpa A et al. PLoS One 2013;8(11):e Creative Commons License
52 Challenge in molecular diagnostics Scarpa A et al. PLoS One 2013;8(11):e Creative Commons License
53 The future in molecular diagnostics Highly selective testing Stepwise, single-gene testing algorithms tailored to specific cancers Multiplex testing Simultaneous multigene and multiplexed approach Unbiased testing Global and unbiased whole-genome approach EGFR mutation DNA RNA DNA RNA KRAS mutation Multiplexed mutation testing Multiplexed RNA profiling and fusion transcript detection Whole-exome (or genome) sequencing Whole-transcriptome sequencing (including paired ends) ALK fusion Genomic copy number profiling Present Future Taylor BS and Ladanyi M. J Pathol 2011;223(2):
54 The future in molecular diagnostics Whole Genome Sequencing Single nucleotide variations Copy number variations Epigenetic changes Structural alterations: Courtesy of Biankin A.
55 The future in molecular diagnostics Next Generation Histopathological diagnosis Patient XY Scarpa A. et al., unpublished data
56 The future in molecular diagnostics Liquid biopsy: Circulating Tumour Cells and DNA Reprinted by permission from Macmillan Publishers Ltd: Crowley E et al. Nat Rev Clin Oncol 2013;10(8): (2013)
57 The future in molecular diagnostics Liquid biopsy: Digital PCR Partition PCR Quantification Scarpa A. et al., unpublished data
58 The future in molecular diagnostics Liquid biopsy: Digital PCR KRAS G12R 1/ MUT MUT+WT Mut Mut+wt background wt WT wt Scarpa A. et al., unpublished data
59 Take home messages Cancers of the same histopathological category differ for their molecular anomalies; i.e. even the most frequent cancer types are a collection of rare diseases from the molecular standpoint Each cancer has multiple gene alterations that affect the function of several signalling pathways, that may be peculiar to a cancer type or similar among different tumour types Molecular heterogeneity is an ongoing process that is responsible for the clonal evolution of cancers in both primary sites and metastasis
60 Take home messages cont. Next-generation sequencing is a cost effective technology for the identification and quantification of molecular heterogeneity; it allows sequencing of multiple genes simultaneously from routine materials, such as small biopsies and cytological samples Further technological and bio-informatic improvements are needed for the introduction into routine use of liquid biopsies (circulating DNA) to evaluate tumour load and monitor response to therapy, and whole genome/transcriptome sequencing to assess the molecular landscape of individual cancers.
61 THANK YOU!
Genomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationEBUS-TBNA Diagnosis and Staging of Lung Cancer
EBUS-TBNA Diagnosis and Staging of Lung Cancer Nirag Jhala MD, MIAC Professor of Pathology and Lab Med. Director of Anatomic Pathology and Cytopathology Lewis Katz School of Medicine@ Temple University
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationDiagnostica Molecolare!
Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationIdentification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins
Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationDiagnostic application of SNParrays to brain cancers
Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL
More informationSupplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each
Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each mutated gene and the panel of 125 cancer-driving genes
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature13898 Supplementary Information Table 1 Kras mutation status of carcinogen-induced mouse lung adenomas Tumour Treatment Strain Grade Genotype Kras status (WES)* Kras status (Sanger) 32T1
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationSupplementary Figure 1. Copy Number Alterations TP53 Mutation Type. C-class TP53 WT. TP53 mut. Nature Genetics: doi: /ng.
Supplementary Figure a Copy Number Alterations in M-class b TP53 Mutation Type Recurrent Copy Number Alterations 8 6 4 2 TP53 WT TP53 mut TP53-mutated samples (%) 7 6 5 4 3 2 Missense Truncating M-class
More informationVertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationThe Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley
The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley Department of Genetics Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill What is TCGA? The Cancer Genome
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Systematic investigation of cancer-associated somatic point mutations in SNP databases HyunChul Jung 1,2, Thomas Bleazard 3, Jongkeun Lee 1 and Dongwan Hong 1 1. Cancer Genomics
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationSALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.
SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 Genomic alterations detectable in cfdna of EGFR-mutant p.t790m-positive and p.t790m-negative patients. (a-b) Lolliplots of gene level alterations in EGFR-mutant p.t790m mutant positive
More informationNew molecular targets in lung cancer therapy
New molecular targets in lung cancer therapy Giuseppe Pelosi Pathology Division, Science & Technology Park, IRCCS Multimedica, Milan Milan - Italy Advanced lung cancer (IIIB IV) Subtyping Oncogene addiction
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationBiology of cancer development in the GI tract
1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationEvolución Clonal de los Tumores y Biopsia Líquida en Cáncer de Pulmón
Evolución Clonal de los Tumores y Biopsia Líquida en Cáncer de Pulmón Ignacio I. Wistuba, M.D. Professor and Chair Department of Translational Molecular Pathology The University of Texas M. D. Anderson
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationTargeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma
Original Article Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma Tumor Biology September 2018: 1 9 Ó The Author(s) 2018 Article reuse
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationUNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY. Giorgio V. Scagliotti University of Torino Dipartment of Oncology
Giorgio V. Scagliotti University of Torino Dipartment of Oncology giorgio.scagliotti@unito.it Molecular landscape of MM not fully characterized to allow personalized treatment Recurrent genetic alterations
More informationThe Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationThe Next Generation in Cancer Diagnostics.
The Next Generation in Cancer Diagnostics. OncoTarget was created specifically for cancer patients. Every patient s cancer is unique, which is why discovering what makes it unique can be essential for
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationThe mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationRound Table: Tissue Biopsy versus Liquid Biopsy. César A. Rodríguez Hospital Universitario de Salamanca-IBSAL
Round Table: Tissue Biopsy versus Liquid Biopsy César A. Rodríguez Hospital Universitario de Salamanca-IBSAL Introduction Classic Advantages of liquid biopsy collection over standard biopsy Standard biopsy
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationSupplementary Figure 1. Estimation of tumour content
Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent
More informationIMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY
Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationADRL Advanced Diagnostics Research Laboratory
ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationThe role of liquid biopsies in the treatment of advanced colon cancer
The role of liquid biopsies in the treatment of advanced colon cancer Clara Montagut Hospital del Mar, Barcelona ESMO CRC Preceptorship Valencia, May 12, 2017 1 ESMO consensus guidelines for the management
More information